Market Overview

UPDATE: Citigroup Reiterates Neutral Rating, Raises PT for Boston Scientific

Share:
Related BSX
Needham Calls Boston Scientific's Results Just 'Decent'
Boston Scientific Posts In-Line Q1 Earnings, Issues Weak Outlook
Boston Scientific on the hook for $100M in Delaware transvaginal mesh trial (Seeking Alpha)

In a company update published earlier today, Citigroup Inc. reiterated its Neutral rating for the Boston Scientific Corporation (NYSE: BSX) and slightly raised its price target from $6.30 to $6.50.

Citigroup went on to say “In March 2004, Boston Scientific entered an unprecedented new product cycle for a large-capital medical technology company with the U.S. launch of the TAXUS stent. In an attempt to offset a slowing growth profile, Boston Scientific made a bold bid to acquire Guidant for $80 per share. Boston significantly overpaid for Guidant, which has led to significant earnings dilution and a high debt load, in our view. More recently, a slow recovery for the ICD business and launch of next-generation Promus drug-eluting stent have pressured gross margins, which should only abate when the in-house manufactured Promus Element reaches the US in mid-2012. Liquidity issues remain an overhang with significant debt overhang and unsettled legal issues.”

Boston Scientific Corporation closed yesterday at $6.31.

Latest Ratings for BSX

DateFirmActionFromTo
Apr 2015BarclaysMaintainsOverweight
Apr 2015Leerink SwannMaintainsOutperform
Apr 2015RBC CapitalMaintainsOutperform

View More Analyst Ratings for BSX
View the Latest Analyst Ratings

Posted-In: Citigroup Inc.Analyst Color Price Target Reiteration Analyst Ratings

 

Related Articles (BSX)

Around the Web, We're Loving...

Get Benzinga's Newsletters